Trump Signs Executive Order to Cut Drug Prices…Benefits for Korean biosimilars? 작성일 04-17 127 목록 <strong class="summary_view" data-translation="true">Order encourages generics, biosimilars to compete with high-cost drugs<br>PBMs face fee disclosure, regulatory pressure</strong> <div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> <section dmcf-sid="bWLIoUBWmS"> <p contents-hash="fc3c44902adc2cd89943e26343ac99f55a1e18a4be528677aa7445f39adbd644" dmcf-pid="KYoCgubYsl" dmcf-ptype="general"> [Kim Saemi, Edaily Reporter] U.S. President Donald Trump on April 15 signed an executive order aimed at lowering the cost of high-priced prescription drugs, a move that could benefit Korean biosimilar manufacturers.</p> <figure class="figure_frm origin_fig" contents-hash="064ad7f481aaa4f3fba2d94933ee01a407449f2e3512154b46fc60a698711de6" dmcf-pid="9Ggha7KGDh" dmcf-ptype="figure"> <p class="link_figure"><img alt="U.S. President Donald Trump (Source = AP Yonhapnews)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202504/17/Edaily/20250417091115644mvcs.jpg" data-org-width="374" dmcf-mid="BKWzYnNfIv" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202504/17/Edaily/20250417091115644mvcs.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> U.S. President Donald Trump (Source = AP Yonhapnews) </figcaption> </figure> <div contents-hash="11561215365e29a67468bac949ea9c8bccd418e246746b7a28baba1949339303" dmcf-pid="2HalNz9HDC" dmcf-ptype="general"> According to the WHITE HOUSE on April 15, Trump announced the executive order titled “Lowering Drug Prices by Once Again Putting Americans First.” The order seeks to improve access to affordable medications for American patients by encouraging the development and faster approval of generics and biosimilars. </div> <p contents-hash="9c8837e7c204b7cb6a7332a9662c194d56b7fa055c6d58c6fadcfd1fece52127" dmcf-pid="VXNSjq2XwI" dmcf-ptype="general">The order also directs a 90-day review of drug supply chain intermediaries, including pharmacy benefit managers, or PBMs. These entities will be required to disclose fees and cooperate in creating government-led policy reforms. Public hearings and official reports aimed at curbing anti-competitive behavior by drugmakers are also part of the plan.</p> <p contents-hash="67b11ab33ef2eaefaaf4ca02610811c071a18bb065f43e6cdac86acbc32d4f5e" dmcf-pid="fZjvABVZEO" dmcf-ptype="general">The Trump administration’s move signals a strong push to reform drug pricing. The order explicitly states that it “increases the availability of generics and biosimilars,” leading to expectations that Korean biosimilar makers like Celltrion and Samsung Bioepis could gain an advantage in the U.S. market.</p> <p contents-hash="8a9768b7d04dc89b0dfb18a4224d60e627fd801ecbc334bf6c5b175cf4b59a64" dmcf-pid="45ATcbf5Ds" dmcf-ptype="general">“With policies focused on accelerating biosimilar approvals and fostering competition, biosimilar manufacturers could see expanded market opportunities,” one industry official said. “As pressure on PBMs increases, we expect more biosimilars to be included in formularies, giving patients more treatment choices and supporting the government’s pricing goals.”</p> <p contents-hash="ba9f11d4b8d241d912ae2091cf6ba1410a654cf0cb5f1d49af352a59b4c73f82" dmcf-pid="8prXm4xpmm" dmcf-ptype="general">김새미 (bird@edaily.co.kr) </p> </section> </div> <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p> 관련자료 이전 "봄꽃보다 눈부신 청춘"…템페스트, '언프리즈'로 전한 청량 에너지 (아돌라) 04-17 다음 NHN 신작 ‘다키스트 데이즈’ 24일 OBT 출사표 “이용자 의견 듣고 함께 서비스” 04-17 댓글 0 등록된 댓글이 없습니다. 로그인한 회원만 댓글 등록이 가능합니다.
